Date: 2016-02-10
Type of information: Initiation of the trial
phase:
Announcement: initiation of the trial
Company: Immunovia (Sweden) Lund University (Sweden)
Product: IMMray™systemic lupus erythematosus biomarker signatures
Action
mechanism: diagnostic test/biomarker signature. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis.
Disease: systemic lupus erythematosus (SLE)
Therapeutic area: Autoimmune diseases
Country:
Trial details:
Latest
news: * On February 10th, 2016, Immunovia announced that the company is expanding the applications area of IMMray™, its proprietary antibody biomarker based technology platform, to autoimmune diseases. The company initiates a new program to focus on the development, validation and commercialization of antibody array based tests for differential diagnostics and for prediction/monitoring of flares for systemic lupus erythematosus biomarker. Immunovia and Lund University have started clinical validation studies of systemic lupus erythematosus biomarker signatures. A new group of expert investigators was formed for a large autoimmunity project at the Department of Immunotechnology at Lund University. The principal investigator is Professor Christer Wingren, who developed the IMMray™ technology, together with Immunovia’s founder Prof Carl Borrebaeck. The initial stages of the IMMray™ SLE program are covered by a grant of 2 million SEK from Vinnova, the Swedish Governmental Agency for Innovation Systems.
